HC Wainwright & Co. Maintains Buy on BioCardia, Adjusts Price Target To $25 (1-15 Reverse Stock Split)
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on BioCardia (NASDAQ:BCDA) and adjusts the price target to $25 from $4 following a 1-15 reverse stock split.
August 16, 2024 | 5:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on BioCardia and adjusts the price target to $25 from $4 following a 1-15 reverse stock split.
The maintenance of a Buy rating and a significant increase in the price target from $4 to $25 by a reputable analyst is likely to positively impact investor sentiment. The 1-15 reverse stock split may also make the stock more attractive to institutional investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100